Inducing protein degradation by proteolysis‐targeting chimeras (PROTACs) has gained
tremendous momentum in the field for its promise in the discovery and development of new …

ABSTRACT Introduction PROteolysis-TArgeting Chimeras (PROTACs) allow the selective
degradation of a protein of interest (POI) by the ubiquitin-proteasome system (UPS). With …

Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug
resistance remains an unmet clinical challenge for the treatment of chronic myeloid …

Abstract PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug
development platform. However, most PROTACs have been generated empirically because …

Proteolysis-targeting chimera (PROTAC) that specifically targets harmful proteins for
destruction by hijacking the ubiquitin–proteasome system is emerging as a potent …

Disease Area. Cancer Biological Target. Fusion Protein BCR-ABL Summary. The fusion of
the BCR and ABL1 genes on the Philadelphia chromosome (Ph), arising from a reciprocal …

The BCR–ABL fusion oncoprotein causes chronic myeloid leukemia or acute lymphoblastic
leukemia in Ph+ patients because the ABL kinase is constitutively activated. However …

Chromosomal translocation occurs in some cancer cells, resulting in the expression of
aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia …

Protein degradation is a promising strategy for drug development. Proteolysis-targeting
chimeras (PROTACs) hijacking the E3 ligase cereblon (CRBN) exhibit enormous potential …

Oncoproteins play a vital role in the pathogenesis of myeloid leukemia. Most targeted
therapies for myeloid leukemia are small molecules or monoclonal antibodies that inhibit the …